keyword
MENU ▼
Read by QxMD icon Read
search

Oritavancin

keyword
https://www.readbyqxmd.com/read/29678300/in-vitro-activity-of-oritavancin-against-planktonic-and-biofilm-states-of-vancomycin-susceptible-and-vancomycin-resistant-enterococci
#1
Qun Yan, Melissa J Karau, Robin Patel
We tested the in vitro activity of oritavancin against 60 vancomycin-susceptible enterococci (VSE) and 27 vancomycin-resistant enterococci (VRE). The oritavancin MIC ranged from ≤0.002 to 0.5μg/mL; the minimum biofilm bactericidal concentration ranged from ≤0.002 to 2μg/mL. Oritavancin has promising in vitro activity against VSE and VRE in both planktonic and biofilm states.
March 16, 2018: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29651842/oritavancin-retains-a-high-affinity-for-a-vancomycin-resistant-cell-wall-precursor-via-its-bivalent-motifs-of-interaction
#2
Sierra Bowden, Christine Joseph, Shengzhuang Tang, Jayme Cannon, Emily Francis, Michelle Zhou, James R Baker, Seok Ki Choi
Despite its potent antibacterial activities against drug-resistant Gram-positive pathogens, oritavancin remains partially understood with respect to its primary mode of hydrogen bond interaction with a cell-wall peptide regarding the role of its lipophilic 4'-chlorobiphenyl moiety. Here we report a surface plasmon resonance (SPR) study performed in two cell-wall model surfaces, each prepared by immobilization with a vancomycin-susceptible Lys-d-Ala-d-Ala or vancomycin-resistant Lys-d-Ala-d-Lac peptide. Analysis of binding kinetics performed on the peptide surface showed that oritavancin bound ∼100-1000-fold more tightly than vancomycin on each model surface...
April 20, 2018: Biochemistry
https://www.readbyqxmd.com/read/29567128/oritavancin-in-vitro-activity-against-gram-positive-organisms-from-european-and-united-states-medical-centers-results-from-the-sentry-antimicrobial-surveillance-program-for-2010-2014
#3
M A Pfaller, H S Sader, R K Flamm, M Castanheira, Rodrigo E Mendes
The in vitro activity of oritavancin was assessed against 44,715 gram-positive pathogens causing infections in European and United States (US) hospitals (2010-2014). There were no substantive differences (>±2-fold dilution) in oritavancin MIC50 or MIC90 values for different species/organism groups over time or by region. Oritavancin (99.9% susceptible) showed modal MIC, MIC50 , and MIC90 results of 0.03, 0.03, and 0.06-0.12 mg/L when tested against Staphylococcus aureus, regardless of methicillin susceptibility, year, or region...
February 3, 2018: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/29501059/review-of-oritavancin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections
#4
Ana Alejandra García Robles, Eduardo López Briz, María Dolores Fraga Fuentes, Rocío Asensi Diez, Jesús Francisco Sierra Sánchez
OBJECTIVE: To assess critically oritavancin, a second-generation  lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. METHOD: An evaluation report of oritavancin in Acute Bacterial Skin and Skin  Structure Infections was carried out according to the methodology of the Group  for drug evaluation, standardization and research in drug selection of the  Spanish Society of Hospital Pharmacy (SEFH)1, with the MADRE 4...
March 1, 2018: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/29491695/oritavancin-orbactiv-a-new-generation-lipoglycopeptide-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections
#5
Samantha Rosenthal, Arnold G Decano, Aiman Bandali, Denise Lai, Gregory E Malat, Tiffany E Bias
Oritavancin (Orbactiv): a new-generation lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections.
March 2018: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/29454983/old-and-new-glycopeptide-antibiotics-from-product-to-gene-and-back-in-the-post-genomic-era
#6
REVIEW
Giorgia Letizia Marcone, Elisa Binda, Francesca Berini, Flavia Marinelli
Glycopeptide antibiotics are drugs of last resort for treating severe infections caused by multi-drug resistant Gram-positive pathogens. First-generation glycopeptides (vancomycin and teicoplanin) are produced by soil-dwelling actinomycetes. Second-generation glycopeptides (dalbavancin, oritavancin, and telavancin) are semi-synthetic derivatives of the progenitor natural products. Herein, we cover past and present biotechnological approaches for searching for and producing old and new glycopeptide antibiotics...
March 2018: Biotechnology Advances
https://www.readbyqxmd.com/read/29399598/long-acting-lipoglycopeptides-for-gram-positive-bacteremia-at-the-end-of-life-to-facilitate-hospice-care-a-report-of-3-cases
#7
Rupak Datta, Dayna McManus, Jeffrey Topal, Manisha Juthani-Mehta
Administering and monitoring intravenous antimicrobials may cause discomfort in patients at the end of life and delay transition to hospice. We describe 3 patients with terminal cancer with methicillin-resistant Staphylococcus aureus, Streptococcus gallolyticus , and Granulicatella adiacens bacteremia who were managed with the long-acting lipoglycopeptide oritavancin to facilitate discharge to hospice.
January 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29367298/evaluation-of-non-tissue-culture-versus-tissue-culture-treated-microplates-for-oritavancin-susceptibility-testing
#8
Qun Yan, Melissa J Karau, Robin Patel
Oritavancin is a recently-approved lipoglycopeptide with activity against Gram-positive bacteria (1).….
January 24, 2018: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/29363950/developments-in-glycopeptide-antibiotics
#9
Mark A T Blaskovich, Karl A Hansford, Mark S Butler, ZhiGuang Jia, Alan E Mark, Matthew A Cooper
Glycopeptide antibiotics (GPAs) are a key weapon in the fight against drug resistant bacteria, with vancomycin still a mainstream therapy against serious Gram-positive infections more than 50 years after it was first introduced. New, more potent semisynthetic derivatives that have entered the clinic, such as dalbavancin and oritavancin, have superior pharmacokinetic and target engagement profiles that enable successful treatment of vancomycin-resistant infections. In the face of resistance development, with multidrug resistant (MDR) S...
February 19, 2018: ACS Infectious Diseases
https://www.readbyqxmd.com/read/29358292/single-intravenous-dose-of-oritavancin-for-treatment-of-acute-skin-and-skin-structure-infections-caused-by-gram-positive-bacteria-summary-of-safety-analysis-from-the-phase-3-solo-studies
#10
G Ralph Corey, Jeffery Loutit, Greg Moeck, Matthew Wikler, Michael N Dudley, William O'Riordan
Oritavancin is a lipoglycopeptide with bactericidal activity against Gram-positive organisms. Its rapid concentration-dependent bactericidal activity and long elimination half-life allow single-dose treatment of acute bacterial skin and skin structure infections (ABSSSI). SOLO I and SOLO II were randomized, double-blind studies evaluating the efficacy and safety of a single 1,200-mg intravenous (i.v.) dose of oritavancin versus twice-daily i.v. vancomycin for 7 to 10 days in ABSSSI patients. Safety data from both studies were pooled for safety analysis...
April 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29208562/microbiological-factors-affecting-clostridium-difficile-recurrence
#11
REVIEW
C H Chilton, D S Pickering, J Freeman
BACKGROUND: Recurrent Clostridium difficile infection (rCDI) places a huge economic and practical burden on healthcare facilities. Furthermore, rCDI may impact quality of life, leaving patients in a 'rCDI cycle', and dependant on antibiotic therapy. AIMS: This article discusses the importance of microbiological factors in the development of rCDI. SOURCES: Literature was drawn from a search of PubMed from 2000 onwards with the search term "recurrent Clostridium difficile infection"; and further references quoted within these articles...
December 2, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29121395/multiple-dose-oritavancin-evaluation-in-a-retrospective-cohort-of-patients-with-complicated-infections
#12
Lucas T Schulz, Emily Dworkin, Jennifer Dela-Pena, Warren E Rose
OBJECTIVE: Oritavancin is a lipoglycopeptide antibiotic approved for use in acute bacterial skin and skin structure infections as a single 1200-mg parenteral dose. Because of oritavancin's long half-life and broad gram-positive activity, interest in its use for other infections is high. METHODS: This study is a retrospective cohort evaluation of patients receiving oritavancin at a single academic medical center. All patients receiving more than one dose of oritavancin were included...
January 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29109163/evaluation-of-oritavancin-dosing-strategies-against-vancomycin-resistant-enterococcus-faecium-isolates-with-or-without-reduced-susceptibility-to-daptomycin-in-an-in-vitro-pharmacokinetic-pharmacodynamic-model
#13
Adam Belley, Francis F Arhin, Greg Moeck
The clinical development of nonsusceptibility to the lipopeptide antibiotic daptomycin remains a serious concern during therapy for infections caused by vancomycin-resistant Enterococcus faecium (VREfm). The long-acting lipoglycopeptide oritavancin exhibits potent in vitro activity against VREfm, although its safety and efficacy for treating clinical VREfm infections have not been established. In this study, novel dosing regimens of daptomycin and oritavancin were assessed against both VREfm and daptomycin-nonsusceptible VREfm isolates in an in vitro pharmacokinetic/pharmacodynamic model...
January 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28942574/once-daily-treatments-for-methicillin-susceptible-staphylococcus-aureus-bacteremia-are-they-good-enough
#14
REVIEW
Sylvain A Lother, Natasha Press
PURPOSE OF THE REVIEW: Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compliance and improve healthcare utilization. We reviewed the literature regarding advantages, pitfalls, and efficacy of once-daily treatment options for MSSA bacteremia. RECENT FINDINGS: Several once-daily antibiotics are effective in vitro against MSSA (ceftriaxone, daptomycin, telavancin, dalbavancin, oritavancin, tedizolid, ertapenem, fluoroquinolones, and others), but there is insufficient evidence to support these agents for MSSA bacteremia...
September 23, 2017: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/28882727/newer-glycopeptide-antibiotics-for-treatment-of-complicated-skin-and-soft-tissue-infections-systematic-review-network-meta-analysis-and-cost-analysis
#15
REVIEW
R Agarwal, S M Bartsch, B J Kelly, M Prewitt, Y Liu, Y Chen, C A Umscheid
OBJECTIVES: Skin and soft tissue infections (SSTIs) carry significant economic burden, as well as morbidity and mortality, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Several new MRSA-active antibiotics have been developed, including semisynthetic glycopeptides (telavancin, dalbavancin and oritavancin). Of these, dalbavancin and oritavancin offer extended dosing intervals. METHODS: We performed a systematic review, network meta-analysis and cost analysis to compare the newer glycopeptides to standard care and to each other for the treatment of complicated SSTIs (cSSTI)...
September 4, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28733126/in-vitro-stepwise-selection-of-reduced-susceptibility-to-lipoglycopeptides-in-enterococci
#16
Francis F Arhin, David Lalonde Seguin, Adam Belley, Gregory Moeck
The propensity of oritavancin to select for stably elevated oritavancin minimum inhibitory concentrations (MICs) was studied by serial passaging of strains in broth containing oritavancin for 20days. Seven clinical strains of Enterococcus faecalis and E. faecium were studied; they included vancomycin-susceptible and both VanA and VanB vancomycin-resistant isolates. Stepwise oritavancin selection yielded stably elevated oritavancin MICs in six of the seven strains, with MIC increases ranging from 4-32-fold. By comparison, stepwise selection with comparator agents dalbavancin (4- to >128-fold MIC increases), telavancin (4-8-fold MIC increases) and daptomycin (4-32-fold MIC increases) also yielded selectants with elevated MICs of the respective agents...
July 1, 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/28732783/future-trends-in-the-treatment-of-methicillin-resistant-staphylococcus-aureus-mrsa-infection-an-in-depth-review-of-newer-antibiotics-active-against-an-enduring-pathogen
#17
REVIEW
A M Bal, M Z David, J Garau, T Gottlieb, T Mazzei, F Scaglione, P Tattevin, I M Gould
Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major public health problem. Vancomycin and teicoplanin have been in clinical use for several decades but their drawbacks are well described. In the last 10 years, several antibiotics have been made available for clinical use. Daptomycin and linezolid have been extensively used during this period. Other agents such as ceftaroline, ceftobiprole, dalbavancin, oritavancin, tedizolid and telavancin have been approved by regulatory agencies since 2009...
September 2017: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/28666751/recently-approved-antibacterials-for-methicillin-resistant-staphylococcus-aureus-mrsa-and-other-gram-positive-pathogens-the-shock-of-the-new
#18
REVIEW
Michael Z David, Matthew Dryden, Thomas Gottlieb, Pierre Tattevin, Ian M Gould
A number of novel antimicrobial drugs with activity against Gram-positive bacterial pathogens have been licensed in the past 4 years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci and other antibiotic-resistant Gram-positive pathogens. The advantages and disadvantages of these drugs are not yet fully appreciated. Here we review the five most promising newly approved compounds, namely ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid...
September 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28642145/new-and-improved-a-review-of-novel-antibiotics-for-gram-positive-bacteria
#19
REVIEW
M Abbas, M Paul, A Huttner
BACKGROUND: The number of antibiotics in the pipeline targeting Gram-positive pathogens has increased in recent years. AIMS: This narrative review aims to provide a summary of existing evidence on efficacy, microbiological spectrum and safety of novel systemic antibiotics that have either recently been licensed or completed phase III trials, and possess activity predominantly against Gram-positive organisms. SOURCES: A review of the published literature via the MEDLINE database was performed...
October 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28543367/successful-treatment-of-methicillin-susceptible-staphylococcus-aureus-osteomyelitis-with-oritavancin
#20
Dino J Delaportas, Sandy J Estrada, Matthew Darmelio
Staphylococcus aureus remains the most common causative pathogen in osteomyelitis. New or alternative therapies are often needed to treat S. aureus infections adequately in patients with drug allergies, treatment failures, or drug interactions. Oritavancin is a novel long-acting lipoglycopeptide approved by the U.S. Food and Drug Administration in 2014 for the treatment of acute bacterial skin and skin structure infections. With a terminal half-life of 8-10 days, oritavancin dosing regimens with infrequent parenteral administration now exist to treat infectious diseases such as osteomyelitis that would otherwise require daily dosing of intravenous antimicrobials for weeks; however, clinical experience is lacking...
August 2017: Pharmacotherapy
keyword
keyword
30796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"